Company Profile
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Latest News
Fed Meeting, Inflation, Boeing, Meta, Apple, Exxon, and More to Watch This Week
4 Big Tech earnings reports, a Fed meeting, and $100 oil: It's the busiest week of the quarter
Will Moderna (MRNA) Report Negative Earnings Next Week? What You Should Know
Four Coinbase Executives Exit Or Shift Roles In Just Over Two Weeks
FDA Showdown Week: CAPR, NRXP, REPL And MRNA Face Make-Or-Break Regulatory Decisions
| Sector | Healthcare |
| Industry | Biotechnology |
| Website | https://www.modernatx.com |
| Audit Risk | 7 |
| Board Risk | 6 |
| Overall Risk | 10 |
| Market Cap | 21.45B |
| Forward P/E | -12.9 |
| Trailing Annual Div. Rate | 0 |
| Trailing Annual Div. Yield | 0.00% |
| Trailing EPS | -8.14 |
| Forward EPS | -4.19 |
| Book Value | 18.66 |
| Price-to-Book | 2.9 |
| Enterprise-to-Revenue | 7.89 |
| Enterprise-to-EBITDA | -7.63 |
| Short Ratio | 5.21 |
| Earnings Date | 07/31/2026 |
| Earnings Call Date | 07/31/2026 |
| Earnings Average | -2 |
| Earnings Low | -2.05 |
| Earnings High | -1.95 |
| Revenue Average | 103.10M |
| Revenue Low | 75.00M |
| Revenue High | 155.00M |